Aug 31, 2023

Featuring perspectives from Dr Michael Wang, including the following topics:

• Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00)
• First- and second-line therapy approaches for MCL (7:26)
• Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who...

Aug 31, 2023

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics:

• Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00)
• Clinical investigation of ibrutinib in the front-line setting;...

Aug 30, 2023

Featuring perspectives from Dr Richard F Riedel, including the following topics:

• Introduction: (0:00)
• Case: A woman in her late 20s with multiregimen-recurrent metastatic alveolar soft part sarcoma after treatment with multiple VEGF tyrosine kinase inhibitors and a single-agent PD-1 inhibitor receives...

Aug 29, 2023

Featuring an interview with Dr Jeremy Abramson, including the following topics:

• Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00)
• Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31)
• Chimeric antigen...

Aug 29, 2023

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics:

• Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00)
• Extended follow-up results with...